김혜민 (경북대학교)

윤영란 (경북대학교)

김혜민 (경북대학교)

박선영 (경북대학교 )

윤영란 (경북대학교)

Dapagliflozin is a medication used to treat type 2 diabetes by lowering blood sugar levels. It works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidney, which promotes the excretion of glucose in the urine. This mechanism also induces weight loss due to energy loss and a metabolic shift towards the utilization of fatty acids and ketone bodies. Weight loss has been observed in individuals with both normal and elevated body mass index (BMI). However, the underlying metabolic differences between these groups remain poorly understood. Therefore, this study aimed to investigate the metabolic changes following a 5-day administration of dapagliflozin in healthy Korean individuals, and to compare the differences between two groups depending on body weight: a normal-weight group (n=13, BMI 22.9 [18.8–24.9] kg/m²) and an obese group (n=9, BMI 34.1 [30.0–41.8] kg/m²). The analysis was conducted using UHPLC-QTOF/MS. A total of 55 and 70 endogenous metabolites were significantly altered in the normal-weight and obese groups, respectively, while 38 endogenous metabolites were shared by two groups. Dapagliflozin shifted energy metabolism in both groups; the normal-weight group activated various energy metabolic pathways, whereas the obese group displayed a more pronounced increase in fatty acid oxidation. These findings enhance our fundamental understanding of dapagliflozin-induced metabolic changes in healthy individuals and underscore the metabolic differences between normal-weight and obese groups.